New Study Exposes Hidden Alzheimer’s “Hot Spots” in Rural Maryland and What They Reveal About America’s Growing Healthcare Divide
On Mar. 8, 2026, a new statewide spatial analysis of Alzheimer’s disease and related dementias (ADRD) has uncovered…
-
-
Study Shows Life forms can planet hop on asteroid debris—and survive
On Mar. 3, 2026, a Johns Hopkins university study shows major impacts could transport life between planets. Tiny…
-
Novartis settles with Henrietta Lacks’ estate over use of her ‘stolen’ cells to advance medicine
On Feb. 26, 2026, Novartis announced it has settled a lawsuit by the estate of Henrietta Lacks that…
-
Novartis settles 18-month-old lawsuit from estate of Baltimore woman whose cells were extracted 75 years ago
On Feb. 24, 2026, The family of a Baltimore woman whose cells were extracted for medical research without…
-
Study reveals genetic factors influencing pregnancy loss
On Jan. 21, 2026, a Johns Hopkins University-led team demonstrated robust connections between specific variations in a mother’s…
-
Biotechnology | CMO | CRO | Genomics | Therapeutics | Vaccine
Samsung Biologics Expands U.S. Manufacturing Capabilities with Acquisition of Human Genome Sciences from GSK
On Dec. 21, 2025, Samsung Biologics announced that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered…
-
Artificial Intelligence | Biotechnology | Chemistry | Energy | Genomics | Infectious Disease | Medical Device | Neurology | Oncology | Pharmaceutical | Stem Cell | Therapeutics | Vaccine
Leiden Report Show Universities in China Dominate Top Ten Rankings
On Oct. 29, 2025, the CWTS Leiden ranking show that Harvard University dropped to third place in the…
-
Biotechnology | Diagnostics | Disease | Neurology | NIH
NIH establishes nation’s first dedicated organoid development center to reduce reliance on animal modeling
On Sept. 25, 2025, the National Institutes of Health (NIH) announced the award of contracts for launching the…
-
GSK to invest $30 billion in R&D and Manufacturing in the U.S. over next 5 years
On Sept. 17, 2025, GSK announced plans to invest $30 billion across the United States in research and…
-
Emergent BioSolutions Receives New Contract for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
On Sept. 9, 2025, Emergent BioSolutions announced that a contract modification has been executed in the amount of…
-
Elutia Announces Sale of BioEnvelope Business to Boston Scientific for $88 Million
On Sept. 9, 2025, Elutia announced it has entered into a definitive agreement to sell its EluPro™ and…
-
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
On Sept. 4, 2025, Novavax announced a milestone payment from Takeda has been triggered by regulatory approval for Novavax’s…
-
Novavax’s Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
On Aug. 27, 2025, Novavax announced that the U.S. Food and Drug Administration (FDA) has approved the Nuvaxovid™ 2025-2026…
-
New Method Advances Reliability of Ai with Applications in Medical Diagnostics
On Aug. 20, 2025, two studies led by Johns Hopkins Kimmel Cancer Center, Ludwig Center, and Johns Hopkins Whiting School of…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Pharmaceutical | Therapeutics | Vaccine
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
On Jul. 22, 2025, AstraZeneca announces $50 billion of investment in the United States by 2030, building on…
-
Supernus Pharmaceuticals to Acquire Sage Therapeutics
On Jun. 16, 2025, Supernus Pharmaceuticals and Sage Therapeutics announced a definitive agreement for Supernus to acquire Sage…
-
Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses in Phase 3 Trial
On Jun. 11, 2025, Novavax announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent…
-
FDA approves Novavax COVID vaccine with new conditions
On May 17, 2025, The U.S. Food and Drug Administration approved Novavax’s COVID-19 vaccine, but placed additional conditions…
-
Gilead boosts planned U.S. investments by $11 billion amid tariff threat
On May 7, 2025, Gilead Sciences announced $11 billion in new planned investment in the U.S. to add…
-
Scientists Unveil the Structure of the Receptor Responsible for How We Taste Sweetness
On May 7, 2025, Howard Hughes Medical Institute Investigator Charles Zuker and members of his Columbia University lab…
-
spinal tumour removed through a person’s eye socket for the first time
On May 6, 2025, in a first-of-its-kind surgery, a multidisciplinary team led by a University of Maryland Medical…
-
Johns Hopkins and Family of Henrietta Lacks Break Ground on Building Named in Honor of Henrietta Lacks
On Oct. 28, 2024, the Johns Hopkins University and Johns Hopkins Medicine, together with descendants of Henrietta Lacks,…
-
Novartis, Viatris face lawsuit over ‘HeLa’ cell misuse claims
On Aug. 5, 2024, Novartis and Viatris were named a federal lawsuit in Maryland by the family of…
-
Novavax’s protein-based non-mRNA COVID-19 vaccine available as additional dose for individuals aged 65 and older
On Feb. 28, 2024, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices…
-
Henrietta Lacks’ family settled lawsuit with biotech company that used her cells without consent
On Aug. 1, 2023, more than 70 years after doctors at Johns Hopkins Hospital took Henrietta Lacks’ cervical…
-
FDA Advisory Committee voted in support of favorable benefit-risk profile for Pfizer’s PAXLOVID
On Mar. 16, 2023, Pfizer announced that the U.S. Food and Drug Administration’s Antimicrobial Drugs Advisory Committee (AMDAC)…
-
Texas A&M scientists disable protective gene In mosquitoes
On Mar. 15, 2023, scientists at Texas A&M announced that a research study: ‘RNA interference is essential to…
-
Howard Hughes Medical Institute’ Codetta Program deciphered genetic code in 250,000 genomes
On Nov. 9, 2021, Howard Hughes Medical Institute announced a program, named Codetta, that can read the genome…
-
Altimmune expanded AdCOVID manufacturing collaboration with Lonza
On Mar. 11, 2021, Altimmune announced that it had expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under the…
-
Novavax confirmed ligh levels of efficacy against original and variant COVID-19 strains in UK and South Africa trials
On Mar. 11, 2021, Novavax announced final efficacy of 96.4% against mild, moderate and severe disease caused by…
